Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-04-01
2010-11-09
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C530S300000, C536S023100
Reexamination Certificate
active
07829526
ABSTRACT:
The present invention is to provide a novel peptide having a potent hypotensive activity by inhibiting cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, or a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient. A search of a genetic data base revealed the presence of a peptide biosynthesized by a processing of unspliced product of TOR2A mRNA. As a result of functional analysis, a peptide hormone exerting a potent bioactivity and expressed abundantly throughout human organs was found. The peptide is hydrophobic with a molecular weight of 2664.02 consisting of 24 amino acids (AIFIFISNTGGKQINQVALEAWRS; SEQ ID NO.: 2) and shows a negative inotropism in rat hearts, as well as a marked systemic hypotensive activity.
REFERENCES:
patent: 2004-008027 (2004-06-01), None
patent: WO 01/32875 (2001-05-01), None
patent: WO 01/32875 (2001-05-01), None
Masayoshi Shichiri et al., Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities, Nature Medicine, Sep. 2003, pp. 1166-1172, vol. 9, No. 9.
Hua Lou and Robert F. Gagel, Alternative Ribonucleic Acid Processing in Endocrine Systems, Endocrine Reviews, 2001, pp. 205-225, The Endocrine Society, vol. 22, No. 2.
Masayoshi Shichiri, Salusins, Jul. 7, 2004, pp. 267-270, vol. 210, No. 4.
Fang Yu et al., Salusins promote cardiomyocyte growth but does not affect cardiac function in rats, Regulatory Peptides, published online on Aug. 18, 2004, pp. 191-197, No. 122, Elsevier.
Hajime Izumiyama et al., Synthetic Salusins as Cardiac Depressors in Rat, Hypertension, Mar. 2005, pp. 419-425, No. 45, American Heart Association.
International Preliminary Report On Patentability and Written Opinion The International Bureau of WIPO, Oct. 19, 2006, Switzerland corresponding to PCT/JP2005/006510.
Japan Science and Technology Agency
Kam Chih-Min
Locke Lord Bissell & Liddell LLP
LandOfFree
Cardioinhibitory/antihypertensive novel endogenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardioinhibitory/antihypertensive novel endogenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardioinhibitory/antihypertensive novel endogenous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208976